A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue

[1]  K. Ulm,et al.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. , 1994, Cancer research.

[2]  R. Abe,et al.  A Cooperative Randomized Controlled Study of Adjuvant Chemoendocrine Therapy for Breast Cancer in Japan , 1994, American journal of clinical oncology.

[3]  R. Collins,et al.  The EBCTCG Overview of Adjuvant Therapy of Breast Cancer , 1993, Annals of the New York Academy of Sciences.

[4]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[5]  F. Jänicke,et al.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. , 1992, Biological chemistry Hoppe-Seyler.

[6]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[7]  M. Duffy.  Do proteases play a role in cancer invasion and metastasis? , 1987, European journal of cancer & clinical oncology.

[8]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[9]  D. Mullins,et al.  The role of proteinase in cellular invasiveness , 1983 .

[10]  S. T. Rohrlich,et al.  The role of proteinases in cellular invasiveness. , 1983, Biochimica et biophysica acta.

[11]  S. Thibodeau,et al.  Simultaneous measurement of estrogen and progesterone receptors in tumor cytosols with use of 125I-labeled estradiol and of 3H-R5020. , 1981, Clinical chemistry.